AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors
October 16 2017 - 7:30AM
AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”) a
company specializing in the development of non-systemic,
recombinant therapies for gastrointestinal diseases today
announced the appointment of Dr. Vern Lee Schramm to the Board of
Directors effective October 10, 2017.
Dr. Schramm has served as Professor of the
Albert Einstein College of Medicine since 1987. Dr. Schramm served
as the Chairman of the Department of Chemistry at the Albert
Einstein College of Medicine from 1987 to 2015. He has been awarded
the Ruth Merns Endowed Chair of Biochemistry. His fields of
interest include enzymatic transition state analysis, transition
state inhibitor design, biological targets for inhibitor design,
and mechanisms of N-ribosyltransferases. Dr. Schramm was elected to
the National Academy of Sciences in 2007, and served as the
Associate Editor for the Journal of the American Chemical Society
from 2003 to 2012. A frequent lecturer and presenter in topics
related to chemical biology, Dr. Schramm has been a consultant and
advisor to Pico Pharmaceuticals, Metabalon Biochemistry, Sirtris
Scientific, and BioCryst Pharmaceuticals.
Dr. Schramm obtained his BS in Bacteriology with
an emphasis in chemistry from South Dakota State College, a
Master’s Degree in Nutrition with an emphasis in biochemistry from
Harvard University, and a Ph.D. in Mechanism of Enzyme Action,
Department of Biochemistry, from Australian National
University.
"I am delighted to welcome Dr. Schramm to the AzurRx Board,"
said Thijs Spoor, CEO of AzurRx BioPharma. "Vern’s substantial
experience at the leading edge of biochemistry and knowledge of the
chemistry related to non-systemic biologics will assist the company
in developing our portfolio of drug candidates."
"I am pleased to be working with the AzurRx team," said Dr.
Schramm, "and look forward to using my experience to help it
further develop its GI and infectious disease therapeutic
portfolio."About AzurRx BioPharma, Inc. AzurRx
BioPharma aims to become a leader in developing non-systemic,
recombinant protein therapies for the treatment of gastrointestinal
diseases and related conditions. MS1819 recombinant lipase for
exocrine pancreatic insufficiency is the company’s lead development
program, and additional early stage research is being conducted for
the prevention of hospital-acquired infection. The company is
headquartered in New York, NY, with scientific operations based in
Langlade, France.Company website
address: www.azurrx.comForward-Looking
Statements This press release may contain certain
statements relating to future results which are forward-looking
statements. These statements are not historical facts, but instead
represent only the Company’s belief regarding future events, many
of which, by their nature, are inherently uncertain and outside of
the Company’s control. It is possible that the Company’s actual
results and financial condition may differ, possibly materially,
from the anticipated results and financial condition indicated in
these forward-looking statements. Additional information concerning
the Company and its business, including factors that potentially
could materially affect the Company’s financial results, are
contained in the Company’s filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become
aware.CONTACT:For more Information: AzurRx BioPharma,
Inc., 760 Parkside Avenue Suite 304 Brooklyn, NY
11226 Phone: (646) 699-7855 info@azurrx.com
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Apr 2024 to May 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From May 2023 to May 2024